From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

The association of Agent Orange exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: A population-based study of Vietnam War era veterans

Last Updated: Monday, February 26, 2024

Agent Orange (AO) exposure is linked with an increased risk of multiple myeloma due to the contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Researchers looked at US veterans to determine whether TCDD/AO exposure increases the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) multiple myeloma. Data will also inform progression risk in patients diagnosed with MGUS with occupational TCDD exposure from herbicides and pesticides. 

Journal of Hematology & Oncology
Advertisement
News & Literature Highlights

Cell Communication and Signaling

CAR-NK cell therapy in multiple myeloma: From preclinical and clinical landscape to joining the force for treatment strategies optimization

Clinical and Experimental Medicine

Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: A systematic review of monoclonal antibodies and fusion proteins in combination strategies

European Journal of Haematology

Prognostic impact of the Hevylite Assay in patients with IgG or IgA multiple myeloma treated within the GMMG-MM5 trial

Blood Reviews

Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity

Supportive Care in Cancer

Symptom distress and fear of progression associated with quality of life in multiple myeloma patients receiving treatment

Frontiers in Oncology

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: Impact of extramedullary and paramedullary disease

Leukemia & Lymphoma

Treatment response assessment using whole body diffusion weighted-magnetic resonance imaging in myeloma: A retrospective cohort study

BMC Pulmonary Medicine

Evaluating pre-transplant nutritional indices as predictors of pneumonia and mortality in multiple myeloma patients post-autologous stem cell transplantation

European Journal of Haematology

From trials to practice: A 2025 review of idecabtagene vicleucel and ciltacabtagene autoleucel efficacy across clinical studies and real-world evidence

Advances in Hematology

Newly diagnosed high-risk multiple myeloma: Outcomes and management

Advertisement
Advertisement